Hugo E. Vargas MD

Hepatology & Liver Transplantation

Physician

Summary

Dr. Hugo E. Vargas is a gastroenterologist based in Scottsdale, AZ, specializing in hepatology and liver transplantation. He earned his medical degree from Drexel University College of Medicine in 1991 and completed his residency in internal medicine at the University of Utah Affiliated Hospitals. He furthered his education with a fellowship in gastroenterology at the University of Pittsburgh Medical Center. Dr. Vargas has held several esteemed positions, including Division Chair and Director of Clinical Research at Mayo Clinic Arizona. His experience includes general hepatology, liver transplantation with an interest in viral hepatitis, alcohol related liver disease and metabolic liver diseases. He has published extensively and serves as a principal investigator for multiple clinical trials. His work has been recognized with CMS Meaningful Use Certifications from Cerner Corporation and other institutions from 2014 to 2017.

CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2014-2017
CMS Meaningful Use Stage 2 Certification FirstNet (CQM), Cerner Corporation, 2014-2017
CMS Meaningful Use Stage 2 Certification Security Audit Manager, Iatric Systems, Inc., 2014-2017

PubMed

U.S. Experience with Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results from the HRS Harmony Consortium.
Kavish R Patidar, Giuseppe Cullaro, Eric S Orman, J Pedro Teixeira, Javier A Neyra
Clinical Gastroenterology and Hepatology. 2026-05-08
Predicting MASLD in People With HIV Using Anthropometric Measures: A Multicenter Cross-Sectional Study.
Jihad Slim, Murad Qirem, Paul Bellafiore, Bereket Tewoldemedhin, Tala B Shahin
Open Forum Infectious Diseases. 2026-05-01
How We Approach It: Alfapump.
Hugo E Vargas, Martha Grace Knuttinen, Lisa Rotellini Coltvet, Jill Kocourek
The American Journal of Gastroenterology. 2026-01-01

Journal Articles

Hepatitis c guidance: aasld-idsa recommendations for testing, managing, and treating adults infected with hepatitis c virus
Chung RT, Davis GL, Jensen DM, Masur H, Saag MS, Thomas DL, Aronsohn AI, Charlton MR, Feld JJ, Fontana RJ, Ghany MG, Godofsky EW, Graham CS, Kim AY, Kiser JJ, Kottilil..., Hepatology, 1/1/2015
Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET
Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M, Peter J, Nelson DR, Fried MW, Reddy KR, on behalf of the HCV-T..., Journal of Hepatology, 1/1/2015
Care of the patient with cirrhosis
Yadav A, Vargas HE, Clinical Liver Disease, 1/1/2015

Books/Book Chapters

Gastroenterology and hepatology board review
Chapter: Drug-induced, granulomatous, and other inflammatory hepatic diseases
Page 389 - 398Gallegos-Orozco JF, Vargas HEEditors: DiBaise JK.McGraw-Hill Medical, New YorkEdition 3rd,2012
Practical gastroenterology and hepatology. Liver and biliary disease
Talley NJ, Lindor KDWiley-Blackwell, Chichester; Hoboken2010
Practical gastroenterology and hepatology. Liver and biliary disease
Chapter: Hepatic complications of bone marrow transplantation
Page 275 - 287Curtis KK, Slack JLEditors: Talley NJ; Lindor KD; Vargas HE.Wiley-Blackwell, Chichester; Hoboken2010

Abstracts/Posters

Changes in Tacrolimus Metabolism in Post-LT Recurrent HCV Treatment with DAA Regimens
Vargas HE, Special Conference on Hepatitis C, American Association for the Study of Liver Diseases (AASLD)/European Association for the Study of the Liver (EASL), New York, NY, 1/1/2014
Advances in HCV Therapy
Vargas HE, Mayo Infection and Immunity Research Club, Rochester, MN, 1/1/2014
The Child-Turcotte-Pugh (CTP) score is best at predicting 6-week mortality in patients with acute variceal hemorrhage (avh): analysis of a US multi-center prospective ...
Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng YH, Fallon MB, Sigal S, Chalasani NP, Lim JK, Reuben A, Abrams G, Lewis MB, Hassanein T, Trotter JF, Sanyal AJ, Beavers K..., Hepatology, 1/1/2014

Lectures

Current and Future Management of Prior Difficult-to-Treat HCV Patients
Houston, TX - 1/1/2015
Debate: Treat All Stages of Fibrosis of Chronic-HCV Now!
Houston, TX - 1/1/2015
2014: The Year HCV Treatment Came of Age: Implications for the LT Population
Mayo Clinic, Phoenix, AZ - 1/1/2014

HCV Quasispecies Dynamics And Liver TransplantNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2005
HCV Quasispecies Dynamics And Liver TransplantNational Institute Of Diabetes And Digestive And Kidney Diseases2003